A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis

Current Medical Research and Opinion

Volumn 23, Issue 11, 2007, Pages 2637-2645

  Klausner, Howard A ^a   Brown, Patricia ^b   Peterson, Janet ^c   Kaul, Simrati ^c   Khashab, Mohammed ^c   Fisher, Alan C ^c   Kahn, James B ^c  

^a HENRY FORD HOSPITAL   (United States)

^b DETROIT RECEIVING HOSPITAL   (United States)

^c Ortho McNeil Pharmaceutical Incorporated   (United States)

Author keywords

Acute pyelonephritis; Ciprofloxacin; Complicated pyelonephritis; Levofloxacin

Indexed keywords

AMPICILLIN; CIPROFLOXACIN; COTRIMOXAZOLE; LEVOFLOXACIN; METICILLIN; PLACEBO; QUINOLONE DERIVATIVE;

ACUTE PYELONEPHRITIS; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HEMOLYTIC ANEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEPHROLITHIASIS; PELVIC INFLAMMATORY DISEASE; PNEUMONIA; POPULATION RESEARCH; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; THORAX PAIN; URINE RETENTION;

ACUTE DISEASE; ADULT; AGED; ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; PYELONEPHRITIS;

EID: 36349000346     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X233340     Document Type: Article

References (19)

1. Sobel JD, Kaye D. Urinary tract infections. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. Philadelphia: Elsevier, 2005:875-905
2. Foxman BF. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002;113:5-13S
3. Foxman B, Klemstine KL, Brown PD. Acute pyelonephritis in US hospitals in 1997: hospitalization and in-hospital mortality. Ann Epidemiol 2003;13:144-50
4. Brown P, Moran K, Foxman B. Acute pyelonephritis among adults: cost of illness and considerations for the economic evaluation of therapy. Pharmacoeconomics 2005;23:1123-42
5. Hooton TM. The current management strategies for community-acquired urinary tract infection. Infect Dis Clin North Am 2003;17:303-32
6. Drusano GL, Preston SL, Fowler C, et al. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 2004;189:1590-7
7. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993;37:1073-81
8. Lister PD. Pharmacodynamics of 750mg and 500mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2002;44:43-9
9. Zhanel GG, Ennis K, Vercaigne L, et al. A critical review of the fluoroquinolones: focus on respiratory tract infections. Drugs 2002;62:13-59
10. Drusano GL, Johnson DE, Rosen M, Standiford HC. Pharmacodynamics of a fluoroquinolone antibacterial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993;37:483-90
11. Jumbe N, Louie A, Leary R, et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 2003;112: 275-85
12. Stein GE, Schooley S, Nicolau D. Bactericidal activity of levofloxacin (750mg) against fluoroquinolone-resistant uropathogens. Presented at the 16th European Congress of Clinical Microbiology and Infectious Diseases, Nice, France, April 1-4, 2006
13. Chien SC, Wong FA, Fowler CL, et al. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-mg and 1-g doses of levofloxacin in healthy volunteers. Antimicrob Agents Chemother 1998;42:885-8
14. Gotfried MH, Danziger LH, Rodvold KA. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 2001;119:1114-22
15. Talan DA, Stamm WE, Hooton TM, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women. JAMA 2000;283:1583-90
16. Naber KG, Bartnicki A, Bischoff W, et al. Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections. Int J Antimicrob Agents 2004;23(Suppl 1):S41-53
17. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003;37:752-60
18. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-72
19. Gail M, Simon R. Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 1985;41: 361-72